{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["pembrolizumab","paclitaxel"]],"indication":"HR+/HER2- non-luminal advanced breast cancer after CDK4/6-inhibitor progression","name":"TATEN","nct_id":"NCT04251169","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=taten-nct04251169. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TATEN","arms":[{"description":"Pembrolizumab 200 mg every 3 weeks (on Day 1 \\[D1\\] of each 21-day cycle, beginning in Cycle 1) in combination with paclitaxel 80 mg/m² administered at Days 1, 8, and 15 of each 21-day cycle beginning at Cycle 2.","label":"Pembrolizumab + Paclitaxel","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2024-04-30","type":"ACTUAL"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":20,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["NSC-125973"],"type":"DRUG"}],"last_update":"2025-06-03","lead_sponsor":"SOLTI Breast Cancer Research Group","official_title":"Targeting Non-Luminal Disease by PAM50 With Pembrolizumab + Paclitaxel in Hormone Receptor-positive/HER2-negative Advanced/Metastatic Breast Cancer, Who Have Progressed on or After CDK 4/6 Inhibitor Treatment","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-04-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Response Rate of Pembrolizumab in Combination With Paclitaxel in HR+/HER2- Non-luminal Subtype Advanced Breast Cancer Defined by the PAM50 Assay","timeFrame":"From the date of randomization to disease progression, death, unacceptable toxicity, consent withdrawal, or study termination, whichever occurred first, assessed for up to 33 months."}],"references":[],"start_date":{"date":"2020-07-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression","url":"https://clinicaltrials.gov/study/NCT04251169"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/taten-nct04251169"}